2 completed, 2 unknown, 1 terminated, 1 withdrawn. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow CT-322: new trials by email Literature Review of CT-322 trials Research Report on CT-322
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Japanese Phase 1 Study of BMS-844203 (CT322) BMS-844203 (CT-322) - Neoplasms | Phase 1 | Withdrawn | Bristol-Myers Squibb | 2013-11-01 | 2012-02-07 | |
| Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer Irinotecan, 5-Fluorouracil (bolus), 5-Fluorouracil (infusional) - Colorectal Cancer (CRC) | Phase 2 | Completed | Bristol-Myers Squibb | 17 | 2009-10-01 | 2015-10-12 |
| Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer Paclitaxel, Carboplatin, CT-322 - Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Terminated | Bristol-Myers Squibb | 255 | 2009-06-01 | 2015-10-12 |
| CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme CT-322, Temozolomide, Radiation Therapy - Glioblastoma Multiforme | Phase 1 | Unknown | Adnexus, A Bristol-Myers Squibb R&D Company | 30 | 2008-10-01 | 2010-10-27 |
| CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan CT-322, irinotecan hydrochloride - Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme | Phase 2 | Unknown | Adnexus, A Bristol-Myers Squibb R&D Company | 72 | 2007-10-01 | 2010-10-27 |
| CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma CT-322 - Cancer | Phase 1 | Completed | Adnexus, A Bristol-Myers Squibb R&D Company | 40 | 2006-08-01 | 2009-02-24 |
Glioblastoma (2) · Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1)
Adnexus, A Bristol-Myers Squibb R&D Company (3) · Bristol-Myers Squibb (3)
United States (5) · Italy (2) · Argentina (1) · Brazil (1) · France (1) · Japan (1) · Poland (1) · Russia (1) · South Africa (1) · United Kingdom (1)